Haloperidol (Haldol)

Category:

  • Miscellaneous

 Description:

  • Antipsychotic

Indications:

  • Psychoses, Gilles de la Tourette syndrome, severe behavioral problems

  • Hyperactive children (short term)

  • Prolonged parenteral neuroleptic therapy for chronic schizophrenia (decanoate)

Contraindications:

  • Severe toxic CNS depression, Parkinson’s disease

  • Comatose states from any cause

Precautions:

  • Pregnancy category C; has been used for hyperemesis gravidarum, chorea gravidarum, and manic depressive illness during pregnancy; excreted in breast milk; effect on nursing infant unknown, but may be of concern

  • Elderly, severe cardiac disorders, seizure disorder

  • Hepatic dysfunction, child < 3 years, alcohol withdrawal

  • Abrupt withdrawal, glaucoma

Adverse Reactions (Side Effects):

  • CNS: agitation, anxiety, catatonic-like behavioral states, confusion, depression, drowsiness, EPS (pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia), euphoria, exacerbation of psychotic symptoms including hallucinations, headache, lethargy, neuroleptic malignant syndrome, restlessness, seizures, vertigo

  • CV: ECG changes, hypertension, hypotension, tachycardia

  • EENT: blurred vision, cataracts, dry eyes, glaucoma, retinopathy

  • GI: anorexia, constipation, diarrhea, dry mouth, dyspepsia, hypersalivation, nausea, vomiting

  • GU: priapism, urinary retention

  • HEME: agranulocytosis, anemia, leukocytosis, minimal decreases in red blood cell counts, transient leukopenia

  • METAB: breast engorgement, gynecomastia, hyperglycemia, hyperprolactinemia, impotence, increased libido, lactation, mastalgia, menstrual irregularities

  • RESP: bronchospasm, increased depth of respiration, laryngospasm

  • SKIN: diaphoresis, loss of hair, isolated cases of photosensitivity, maculopapular and acneiform skin reactions  

Dosage:

Administered orally and intramuscularly

  • Adult:            

    • Psychosis/Tourette’s syndrome: PO 0.5-5mg 2-3 times daily initially depending on severity of condition, dose is increased to desired dose, max 100mg daily; IM 2-5mg every 1-8 hours

    • Chronic schizophrenia: IM 10-15 times the individual patient’s stabilized PO dose every 4 weeks (decanoate)

  • Child 3-12 years: 

    • Psychosis: PO/IM 0.05-0.15 mg/kg/day in 2-3 divided doses

    • Tourette’s syndrome: PO 0.05-0.075 mg/kg/day in 2-3 divided doses

    • Hyperactivity: PO 0.05-0.075 mg/kg/day in 2-3 divided doses

Special considerations:

Do not mix liquid formulation with coffee or tea

Use calibrated dropper

Take with food or milk

Arise slowly from reclining position

Do not discontinue abruptly

Use a sunscreen during sun exposure to prevent burns

Take special precautions to stay cool in hot weather

Observe closely for signs of tardive dyskinesia

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site